UBS AM
LXEO icon

UBS AM’s Lexeo Therapeutics LXEO Stock Holding History

UBS AM’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261 Hold
56
– – ﹤0.01% 3688
2026
Q1 		$321 Buy
+56
New +$397 ﹤0.01% 3748

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

UBS AM's LXEO Position: Q2 2026 in Review

UBS AM held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 56 shares worth $261. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

UBS AM first reported a position in LXEO in Q1 2026 and has held it in 2 quarters since. The position peaked at $321 in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • UBS AM held 56 shares of Lexeo Therapeutics worth $261 as of Q2 2026.
  • UBS AM left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3688 holding.
  • UBS AM first reported a position in Lexeo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • UBS AM's Lexeo Therapeutics position peaked at $321 in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.